| Relation: |
https://www.ped-perinatology.ru/jour/article/view/1850/1396; Mieli-Vergani G., Vergani D., Baumann U., Czubkowski P., Debray D., Dezsofi A. et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2018; 66(2): 345–360. DOI:10.1097/MPG.0000000000001801; Webb G.J., Hirschfield G.M., Krawitt E.L., Gershwin M.E. Cellular and Molecular Mechanisms of Autoimmune Hepatitis. Annu Rev Pathol 2018; 13: 247–292. DOI:10.1146/annurev-pathol-020117–043534; Mieli-Vergani G., Vergani D., Czaja A.J., Manns M.P., Krawitt E.L., Vierling J.M. et al. Autoimmune hepatitis. Nat Rev Dis Primers 2018; 4: 18017. DOI:10.1038/nrdp.2018.17; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63(4): 971–1004. DOI:10.1016/j.jhep.2015.06.030; Corrigan M., Hirschfield G.M., Oo Y.H., Adams D.H. Autoimmune hepatitis: an approach to disease understanding and management. Br Med Bull 2015; 114(1): 181–91. DOI:10.1093/bmb/ldv021; Manns M.P., Lohse A.W., Vergani D. Autoimmune hepatitis — Update 2015. J Hepatol 2015; 62(1 Suppl): S100–11. DOI:10.1016/j.jhep.2015.03.005; de Boer Y.S., van Gerven N.M., Zwiers A., Verwer B.J., van Hoek B., van Erpecum K.J. et al.; Dutch Autoimmune Hepatitis Study Group; LifeLines Cohort Study; Study of Health in Pomerania. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014; 147(2): 443–52.e5. DOI:10.1053/j.gastro.2014.04.022; Webb G.J., Hirschfield G.M. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun 2016; 66: 25–39. DOI:10.1016/j.jaut.2015.08.016; Adolph T.E., Grander C., Moschen A.R., Tilg H. Liver-Microbiome Axis in Health and Disease. Trends Immunol 2018; 39(9): 712–723. DOI:10.1016/j.it.2018.05.002; Kummen M., Holm K., Anmarkrud J.A., Nygård S., Vesterhus M., Høivik M.L. et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2017; 66(4): 611–619. DOI:10.1136/gutjnl-2015–310500; Sabino J., Vieira-Silva S., Machiels K., Joossens M., Falony G., Ballet V. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016; 65(10): 1681–1689. DOI:10.1136/gutjnl-2015–311004; Tang R., Wei Y., Li Y., Chen W., Chen H., Wang Q. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018; 67(3): 534–541. DOI:10.1136/gutjnl-2016–313332; Tripathi A., Debelius J., Brenner D.A., Karin M., Loomba R., Schnabl B. et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018; 15(7): 397–411. DOI:10.1038/s41575–018–0011-z; Yuksel M., Wang Y., Tai N., Peng J., Guo J., Beland K. et al. A novel «humanized mouse» model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 2015; 62(5): 1536–1550. DOI:10.1002/hep.27998; Manfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N. et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018; 359(6380): 1156–1161. DOI:10.1126/science.aar7201; Abe K., Takahashi A., Fujita M., Imaizumi H., Hayashi M., Okai K. et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One 2018; 13(7): e0198757. DOI:10.1371/journal.pone.0198757; Lv L., Jiang H., Chen X., Wang Q., Wang K., Ye J. et al. The Salivary Microbiota of Patients With Primary Biliary Cholangitis Is Distinctive and Pathogenic. Front Immunol 2021; 12: 713647. DOI:10.3389/fimmu.2021.713647; He Y., Wu W., Zheng H.M., Li P., McDonald D., Sheng H.F. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med 2018; 24(10): 1532–1535. DOI:10.1038/s41591–018–0164-x; Huttenhower C., Gevers D., Knight R., Abubucker S., Badger J.H., Chinwalla A.T. et al. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486(7402): 207–14. DOI:10.1038/nature11234; David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505(7484): 559–563. DOI:10.1038/nature12820; Sonnenburg E.D., Smits S.A., Tikhonov M., Higginbottom S.K., Wingreen N.S., Sonnenburg J.L. Diet-induced extinctions in the gut microbiota compound over generations. Nature 2016; 529(7585): 212–215. DOI:10.1038/nature16504; Modi S.R., Collins J.J., Relman D.A. Antibiotics and the gut microbiota. Clin Invest 2014; 124(10): 4212–4128. DOI:10.1172/JCI72333; Maurice C.F., Haiser H.J., Turnbaugh P.J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013; 152(1–2): 39–50. DOI:10.1016/j.cell.2012.10.052; Gabarre P., Loens C., Tamzali Y., Barrou B., Jaisser F., Tourret J. Immunosuppressive therapy after solid organ transplantation and the gut microbiota: Bidirectional interactions with clinical consequences. Am J Transplant 2022; 22(4): 1014–1030. DOI:10.1111/ajt.16836; Sonnenburg J.L., Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 535(7610): 56–64. DOI:10.1038/nature18846; Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J., Holmes S.P. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 2016; 13(7): 581–583. DOI:10.1038/nmeth.3869; Wei Y., Li Y., Yan L., Sun C., Miao Q., Wang Q. et al. Alterations of gut microbiome in autoimmune hepatitis. Gut 2020; 69(3): 569–577. DOI:10.1136/gutjnl-2018–317836; Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol 2013; 11: 639–647. DOI:10.1038/nrmicro3089; Imajo K., Fujita K., Yoneda M., Nozaki Y., Ogawa Y., Shinohara Y. et al. Hyperresponsivity tolow-dose endotoxin during progression to nonalcoholic steatohepatitis isregulated by leptin-mediated signaling. Cell Metab 2012; 16: 44–54. DOI:10.1016/j.cmet.2012.05.012; Gevers D., Kugathasan S., Denson L.A., Vázquez-Baeza Y., Van Treuren W., Ren B. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014; 15: 382–392. DOI:10.1016/j.chom.2014.02.005; Akberova D., Kiassov A.P., Abdulganieva D. Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases. J Immunol Res 2017; 2017: 9829436. DOI:10.1155/2017/9829436; Yoshida N., Emoto T., Yamashita T., Watanabe H., Hayashi T., Tabata T. et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation 2018; 138(22): 2486–2498. DOI:10.1161/CIRCULATIONAHA.118.033714; Koh A., De Vadder F., Kovatcheva-Datchary P., Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 2016; 165(6): 1332–1345. DOI:10.1016/j.cell.2016.05.041; Kriss M., Hazleton K.Z., Nusbacher N.M., Martin C.G., Lozupone C.A. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol 2018; 44: 34–40. DOI:10.1016/j.mib.2018.07.003; Kelly C.J., Zheng L., Campbell E.L., Saeedi B., Scholz C.C., Bayless A.J. et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe 2015; 17(5): 662–671. DOI:10.1016/j.chom.2015.03.005; Wu T., Yang L., Jiang J., Ni Y., Zhu J., Zheng X. et al. Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats. Life Sci 2018; 192: 173–182. DOI:10.1016/j.lfs.2017.11.049; Tourret J., Willing B.P., Dion S., MacPherson J., Denamur E., Finlay B.B. Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. Transplantation 2017; 101(1): 74–82. DOI:10.1097/TP.0000000000001492; He Z., Kong X., Shao T., Zhang Y., Wen C. Alterations of the Gut Microbiota Associated With Promoting Efficacy of Prednisone by Bromofuranone in MRL/lpr Mice. Front Microbiol 2019; 10: 978. DOI:10.3389/fmicb.2019.00978; Huang E.Y., Inoue T., Leone V.A., Dalal S., Touw K., Wang Y. et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis 2015; 21(5): 963–972. DOI:10.1097/MIB.0000000000000332; Steiner R.W., Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol 2011; 33(2): 157–167. DOI:10.1007/s00281–011–0259–7; Rodríguez-Piñeiro A.M., Johansson M.E. The colonic mucus protection depends on the microbiota. Gut Microbes 2015; 6(5): 326–330. DOI:10.1080/19490976.2015.1086057; Bunker J.J., Flynn T.M., Koval J.C., Shaw D.G., Meisel M., McDonald B.D. et al. Innate and Adaptive Humoral Responses Coat Distinct Commensal Bacteria with Immunoglobulin A. Immunity 2015; 43(3): 541–553. DOI:10.1016/j.immuni.2015.08.007; Sommer F., Anderson J.M., Bharti R., Raes J., Rosenstiel P. The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol 2017; 15(10): 630–638. DOI:10.1038/nrmicro.2017.58; Kim H.B., Wang Y., Sun X. A Detrimental Role of Immunosuppressive Drug, Dexamethasone, During Clostridium difficile Infection in Association with a Gastrointestinal Microbial Shift. J Microbiol Biotechnol 2016; 26(3): 567–571. DOI:10.4014/jmb.1512.12017; Liu F., Ma R., Riordan S.M., Grimm M.C., Liu L., Wang Y. et al. Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes. Front Microbiol 2017; 8: 527. DOI:10.3389/fmicb.2017.00527; Swidsinski A., Loening-Baucke V., Bengmark S., Lochs H., Dörffel Y. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis 2007; 13(1): 51–56. DOI:10.1002/ibd.20003; Mousa O.Y., Juran B.D., McCauley B.M., Vesterhus M.N., Folseraas T., Turgeon C.T. et al. Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology 2021; 74(1): 281–295. DOI:10.1002/hep.31652; Watanabe Y., Nagai F, Morotomi M. Characterization of Phascolarctobacterium succinatutens sp. nov., an asaccharolytic, succinate-utilizing bacterium isolated from human feces. Appl Environ Microbiol 2012; 78(2): 511–518. DOI:10.1128/AEM.06035–11; Morgan X.C., Tickle T.L., Sokol H., Gevers D., Devaney K.L., Ward D.V. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13(9): R79. DOI:10.1186/gb-2012–13–9-r79; Horvath T.D., Ihekweazu F.D., Haidacher S.J., Ruan W., Engevik K.A., Fultz R. et al. Bacteroides ovatus colonization influences the abundance of intestinal short chain fatty acids and neurotransmitters. Science 2022; 25(5): 104158. DOI:10.1016/j.isci.2022.104158 |